GURUFOCUS.COM » STOCK LIST » Latin America » Mexico » MEX » Biogen Inc (MEX:BIIB) » Definitions » Cash Flow from Investing
Switch to:

Biogen (MEX:BIIB) Cash Flow from Investing

: MXN27,659 Mil (TTM As of Mar. 2023)
View and export this data going back to 2013. Start your Free Trial

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Mar. 2023, Biogen spent MXN1,200 Mil on purchasing property, plant, equipment. It gained MXN0 Mil from selling property, plant, and equipment. It spent MXN0 Mil on purchasing business. It gained MXN0 Mil from selling business. It spent MXN23,815 Mil on purchasing investments. It gained MXN7,940 Mil from selling investments. It paid MXN90Mil for net Intangibles purchase and sale. And it paid MXN13 Mil for other investing activities. In all, Biogen spent MXN17,178 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Mar. 2023.


Biogen Cash Flow from Investing Historical Data

The historical data trend for Biogen's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cash Flow from Investing
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -40,179.10 8,873.63 -12,106.27 -11,563.74 30,737.39

Biogen Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Cash Flow from Investing Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12,902.33 13,951.83 33,636.30 -2,750.89 -17,177.83

Biogen Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Biogen's Cash Flow from Investing for the fiscal year that ended in Dec. 2022 is calculated as:

Biogen's Cash Flow from Investing for the quarter that ended in Mar. 2023 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN27,659 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biogen  (MEX:BIIB) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Biogen's purchase of property, plant, equipment for the three months ended in Mar. 2023 was MXN-1,200 Mil. It means Biogen spent MXN1,200 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Biogen's sale of property, plant, equipment for the three months ended in Mar. 2023 was MXN0 Mil. It means Biogen gained MXN0 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Biogen's purchase of business for the three months ended in Mar. 2023 was MXN0 Mil. It means Biogen spent MXN0 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Biogen's sale of business for the three months ended in Mar. 2023 was MXN0 Mil. It means Biogen gained MXN0 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Biogen's purchase of investment for the three months ended in Mar. 2023 was MXN-23,815 Mil. It means Biogen spent {stock_data.stock.currency_symbol}}23,815 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Biogen's sale of investment for the three months ended in Mar. 2023 was MXN7,940 Mil. It means Biogen gained MXN7,940 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Biogen's net Intangibles purchase and sale for the three months ended in Mar. 2023 was MXN-90 Mil. It means Biogen paid MXN90 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Biogen's cash from discontinued investing activities for the three months ended in Mar. 2023 was 0 Mil. It means Biogen paid MXN0 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Biogen's cash from other investing activities for the three months ended in Mar. 2023 was MXN-13 Mil. It means Biogen paid MXN13 Mil for other investing activities.


Biogen Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Biogen's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (MEX:BIIB) Business Description

Biogen logo
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Biogen (MEX:BIIB) Headlines